Melena Bellin is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2450 Riverside Ave
Minneapolis, MN 554541450
Telephone
612-365-6777Registry record last updated 19 May 2016.
Clinical trials
- SGLT2i Therapy in Islet Transplantation (SIT)
Sponsor: University of Minnesota
- Diabetes RElated to Acute Pancreatitis and Its Mechanisms
Sponsor: Milton S. Hershey Medical Center
- Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Sponsor: Dompé Farmaceutici S.p.A
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year202533 payments$21,600openpaymentsdata.cms.gov ↗
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
- Insulet CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.9%Calcineurin inhibitor53.9%Tacrolimus100%Part D<11 patientsMetabolism & gastrointestinal
35.1%Antidiarrheal microorganisms24.7%Creon100%Part D<11 patientsInsulin Analog10.4%Lantus Solostar100%Part D<11 patientsAnti-infectives
11%Short-acting sulfonamides11%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
11 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Protein biomarkers to predict pain outcomes after total pancreatectomy with islet autotransplant
University of Minnesota
FY2026$726,035R01DK138809 - University of Minnesota Clinical Center for the Study of Pancreatic Disease
University of Minnesota
FY2026$603,379U01DK126300 - University of Minnesota Clinical Center for the Study of Acute Pancreatitis and Diabetes
University of Minnesota
FY2026$492,800U01DK127367
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”